Similarly, glioblastoma (WHO IV) revealed a higher expression of XPO1 compared to WHO II gliomas, with no differences compared to WHO III gliomas in the TCGA cohort (Figure 2B). This evidence concerns the gene XPO1 and central nervous system cancer.